文献速递姑息放疗与转移瘤胸部肿瘤放疗放疗物理与技术

多中心报告:纳武利尤单抗同步放疗的毒性

Multi-institutional report on toxicities of concurrent nivolumab and radiation therapy.
PubMed 文献 · Adv Radiat Oncol · 2018-05-24

这项多中心回顾性研究纳入2015年1月至2017年5月接受纳武利尤单抗同步放疗的连续患者,46例(17.6%)存在同步放疗,共67个治疗部位。中位随访3.3个月,42例可评估患者中4例(9.5%)出现3级毒性,其中2例归因于加用放疗。作者认为同步纳武利尤单抗放疗似乎未增加既往报道的纳武利尤单抗或放疗单独治疗的毒性。

要点

  • 46例(17.6%)接受纳武利尤单抗同步放疗,共67个治疗部位。
  • 42例可评估患者中4例(9.5%)出现3级毒性,2例归因于加用放疗。
  • 作者认为同步治疗似乎未增加既往报道的单药或单纯放疗毒性。

核心结论

  • 同步纳武利尤单抗放疗似乎未增加既往报道的纳武利尤单抗或放疗单独治疗的毒性率。

研究设计与样本

  • 回顾性审查2015年1月至2017年5月在4个独立中心接受同步纳武利尤单抗放疗的所有连续患者。
  • 同步纳武利尤单抗放疗定义为放疗在首次纳武利尤单抗输注前3天内完成至末次纳武利尤单抗输注后28天内完成。
  • 261例接受纳武利尤单抗的患者中46例(17.6%)存在同步放疗,共67个治疗部位;4例黑色素瘤患者因同步伊匹木单抗被排除出最终毒性分析,最终分析42例。

主要发现

  • 中位随访3.3个月(四分位距1.7-6.1个月),1年总生存率为22%。
  • 末次分析时46例中11例(24%)存活,其中位随访12.8个月(四分位距8.3-14.9个月)。
  • 最常见组织学为非小细胞肺癌(46例中23例;50%),最常见放疗处方为30 Gy分10次(67个部位中24个;35.8%),最常见治疗部位为腹部/盆腔(67个部位中16个;24%)。
  • 同步纳武利尤单抗放疗治疗3个月内,42例中4例(9.5%)发生3级毒性;其中2例毒性具体归因于加用放疗:全脑放疗后3级听力丧失和左肾上腺立体定向体部放疗后3级胰腺炎。
  • 1例转氨酶升高死亡归因于纳武利尤单抗单药,因为放疗野未涵盖肝脏。

关键数值与推荐

  • 纳武利尤单抗单药和单纯姑息放疗的3级及以上毒性率既往报道分别为10%至18%和0%至26%。
  • 同步纳武利尤单抗放疗定义为放疗在首次纳武利尤单抗输注前3天内完成至末次纳武利尤单抗输注后28天内完成。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Radiation therapy (RT) and nivolumab are standard therapies for a wide range of advanced and metastatic cancers, yet little is known about the toxicity profile of their combined treatment. The rate of grade ≥3 toxicities from nivolumab monotherapy and radiation-only palliative treatments has been reported at 10% to 18% and 0% to 26%, respectively. We reviewed our experience to assess the acute toxicity profile of concurrent RT-nivolumab. METHODS AND MATERIALS: A retrospective review of all consecutive patients from January 2015 to May 2017 who received concurrent RT-nivolumab was conducted at 4 separate centers. Concurrent RT-nivolumab was defined as RT completed between 3 days prior to initial nivolumab infusion and 28 days after the last nivolumab infusion. RESULTS: Of the 261 patients who received nivolumab, 46 (17.6%) had concurrent RT to 67 treatment sites. The median follow-up was 3.3 months (interquartile range, 1.7-6.1 months) and the 1-year overall survival rate was 22%. For the 11 of 46 patients (24%) who were alive at last analysis, the median follow-up was 12.8 months (interquartile range, 8.3-14.9 months). The most common histology, RT prescription, and treatment site were non-small cell lung cancer (23 of 46 patients; 50%), 30 Gy in 10 fractions (24 of 67 patients; 35.8%), and abdomen/pelvis (16 of 67 patients; 24%), respectively. Four patients with melanoma had concurrent ipilimumab and were removed from the final toxicity analysis of RT-nivolumab. Within 3 months of treatment with RT-nivolumab, 4 of 42 patients (9.5%) experienced grade 3 toxicity and 2 of these patients' toxicities were attributed specifically to the addition of RT: grade 3 hearing loss after whole brain RT and grade 3 pancreatitis after stereotactic body RT to the left adrenal gland. One death from transaminitis was attributed to nivolumab alone because the RT field did not encompass the liver. CONCLUSIONS: Concurrent RT-nivolumab did not appear to increase the toxicity profile from the previously reported toxicity rates from nivolumab or radiation alone.

来源:Adv Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Amin NP, Zainib M, Parker SM, et al. Multi-institutional report on toxicities of concurrent nivolumab and radiation therapy. Adv Radiat Oncol. 2018. PMID: 30202808. doi:10.1016/j.adro.2018.04.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。